ERBB2 and neoplasm: The obtained 89Zr-labeled conjugates were evaluated in vitro and in vivo in a HER2-positive breast cancer mouse model and compared to non-site-specifically derivatized and 89Zr-labeled trastuzumab with regard to biodistribution and tumor visualization.